Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus results from action in diabetes and vascular disease: Preterax and diamicron mr controlled evaluation

Hypertension

Volumn 65, Issue 1, 2015, Pages 115-121

  Van Der Leeuw, Joep ^b   Visseren, Frank L J ^a   Woodward, Mark ^d   Zoungas, Sophia ^a   Kengne, Andre Pascal ^b   Van Der Graaf, Yolanda ^a   Glasziou, Paul ^c   Hamet, Pavel ^d   MacMahon, Stephen ^e   Poulter, Neil ^f   Grobbee, Diederick E ^g   Chalmers, John ^h  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b General Practice   (Netherlands)

^c UNIVERSITY OF SYDNEY   (Australia)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e BOND UNIVERSITY   (Australia)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antihypertensive Agents; Diabetes Mellitus; Individualized Medicine; Medical Decision

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIDIABETIC AGENT; CHOLESTEROL; CREATININE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; INDAPAMIDE; INDAPAMIDE, PERINDOPRIL DRUG COMBINATION; PERINDOPRIL;

ADVERSE OUTCOME; AGE; AGED; ALGORITHM; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DRUG EFFECT; EVALUATION STUDY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INDAPAMIDE; MALE; PERINDOPRIL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84919427890     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04421     Document Type: Article

References (35)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14
2. van Dieren S, Beulens JW, Van Der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(suppl 1):S3-S8
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665
5. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913-922
6. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S; Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419
7. American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care. 2013;36(suppl 1):S11-S66
8. European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159-2219
9. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2013;1097:1-14
10. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324:1570-1576
11. Dorresteijn JA, Boekholdt SM, Van Der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. Highdose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013;127:2485-2493
12. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, Van Der Graaf Y, Cook NR. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ. 2011;343:d5888
13. Van Der Leeuw J, Ridker PM, Van Der Graaf Y, Visseren FL. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J. 2014;35:837-843
14. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individuals absolute cardiovascular risk. Lancet. 2005;365:434-441
15. van Dieren S, Kengne AP, Chalmers J, Beulens JW, Cooper ME, Grobbee DE, Harrap S, Mancia G, Neal B, Patel A, Poulter N, Van Der Schouw YT, Woodward M, Zoungas S. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83-90
16. Arends LR, Hoes AW, Lubsen J, Grobbee DE, Stijnen T. Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. Stat Med. 2000;19:3497-3518
17. Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: Meta-analysis of randomized trials. J Hypertens. 2011;29:4-16
18. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. BMJ. 2008;336:1121-1123
19. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation. 2013;128:2309-2317
20. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370: 829-840
21. Advance Management Committee. Rationale and design of the advance study: A randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in diabetes and vascular disease: Preterax and diamicron modified-release. J Hypertens Suppl. 2001;19:S21-S28
22. Grobbee DE, Hoes AW. Clinical Epidemiology. Burlington, MA: Jones &Bartlett; 2014
23. Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York, NY: Springer; 2009
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612
25. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85
26. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, Chalmers J, Colagiuri S, Grobbee DE, Hamet P, Heller S, Neal B, Woodward M; ADVANCE Collaborative Group. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011;18:393-398
27. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679
28. Grnnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal. 1996;2:315-328
29. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387
30. Vickers AJ, Kattan MW, Daniel S. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials. 2007;8:14
31. Haffner SM, Lehto S, Rnnemaa T, Pyrl K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234
32. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, Christianson TJ, Mullan RJ, Smith SA. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167:1076-1082
33. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427
34. Kattan MW. Doc, what are my chances? A conversation about prognostic uncertainty. Eur Urol. 2011;59:224
35. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773-785.